Analyst Initiates Buy Rating on Caris, Highlighting Caris Detect Launch and Early Positive Economics
Tip Ranks·- Caris Life Sciences, Inc. was reassessed by Wall Street analysts, with Goldman Sachs maintaining a "buy" rating at a target price of $27.00. - The rating from analyst Evie Koslosky is influenced by the launch of Caris Detect, an early multi-cancer detection test leveraging advanced technologies and showing strong clinical results. - Additionally, BTIG reaffirmed a "buy" rating with a target price of $32.00, highlighting the stock's growth potential in the new market.